Literature DB >> 3424908

[Determination of active components of amrinone by analysis of pressure-volume results; use of the conductance (volume) catheter technic and rapid load change by balloon occlusion of the inferior vena cava].

J Thormann1, W Kramer, M Kindler, P Kremer, M Schlepper.   

Abstract

Endsystolic pressure-volume relationships (ESPVR) were determined using the conductance (volume) catheter-technique and the required rapid load changes by applying vasoactive drugs (nitroprusside = NP; phenylephrine = PE) or brief preload reduction by balloon occlusion of the vena cava inferior (BOVCI). With this load-independent index of contractility, we analyzed the hemodynamically active components of amrinone (AM) over a range of different LV-loading conditions. In 19 patients (study I) with still normal LV-function (LVF) in group A (dP/dtmax 1585 +/- 386 mmHg/s; n = 10) and impaired LVF in group B (dP/dtmax 1044 +/- 164 mmHg/s; n = 9) an infusion of AM, 1.5 mg/kg over 2 min, failed to induce changes in ESPVR (p greater than 0.05), but rather caused load changes, resembling like those seen with NP. During continuously paced heart rates (90/min) brief infusion phases with NP and PE provided the necessary load changes. In 11 patients (study II) with impaired LVF (dP/dtmax = 1177 +/- 163 mmHg/s) 2.5 mg/kg AM i.v. induced an increase in contractility, which was more pronounced after the additional application of dobutamine (DOB) at 10 micrograms/kg/min.; (1) Slope k rose from 0.52 to 0.80 mmHg/ml; (2) dP/dtmax increased by an average of 39% and 57% (p less than 0.01), respectively. The BOVCI provided the necessary load changes. Thus AM demonstrates its contractility-increasing effects in a dose-related fashion, probably (at least in part) via an increase in heart rate; inotropic effects further increased with the combination of AM and DOB. The use of the conductance technique for the assessment of ESPVR during acute decrease of preload by temporary BOVCI is innocuous to the patient, reproducible and can be carried out under the conditions of a routine cardiac catheter procedure. This technique seems to be useful in the assessment of relative inotropic effects of the newer cardiotonic drugs.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3424908

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  8 in total

1.  Noninvasive assessment of the inodilator action of amrinone in healthy man.

Authors:  C de Mey; D Enterling; G Hanft
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Ventricular pressure-volume relations as the primary basis for evaluation of cardiac mechanics. Return to Frank's diagram.

Authors:  R Jacob; G Kissling
Journal:  Basic Res Cardiol       Date:  1989 May-Jun       Impact factor: 17.165

3.  Intermittent Occlusion of the Superior Vena Cava Reduces Cardiac Filling Pressures in Preclinical Models of Heart Failure.

Authors:  Navin K Kapur; Lara Reyelt; Paige Crowley; Lauren Richey; John McCarthy; Shiva Annamalai; Sarah Newman; Lena Jorde; Sina Forotuanjazi; Allen Razavi; Tim Lenihan; Daniel Burkhoff; Richard H Karas
Journal:  J Cardiovasc Transl Res       Date:  2019-11-26       Impact factor: 4.132

4.  Influence of angiotensin converting enzyme inhibition on pump function and cardiac contractility in patients with chronic congestive heart failure.

Authors:  L H Baur; J J Schipperheyn; J Baan; A van der Laarse; B Buis; E E van der Wall; V Manger Cats; A D van Dijk; J A Blokland; M Frölich
Journal:  Br Heart J       Date:  1991-03

Review 5.  Cardiovascular effects of forskolin and phosphodiesterase-III inhibitors.

Authors:  M Schlepper; J Thormann; V Mitrovic
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

6.  Enoximone: true inotropic effects? Do they cause ischemia? Analysis of end-systolic pressure-volume relations using the conductance (volume) catheter technique.

Authors:  J Thormann; J Hueting; P Kremer; J Wissemann; V Mitrovic; H A Dieterich; M Schlepper
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

Review 7.  Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure.

Authors:  T A Fischer; R Erbel; N Treese
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

8.  Influence of the new class I antiarrhythmic agent diprafenone on the end-systolic pressure-volume relationship (conductance technique).

Authors:  J Thormann; W Kramer; P Kremer; M Schlepper
Journal:  Cardiovasc Drugs Ther       Date:  1989-04       Impact factor: 3.727

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.